The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals.

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

On the one hand, its impressive business performance can make investors ponder potential life-changing investment returns. Conversely, feeling confident in Hims & Hers Health can sometimes be ...

If Altimmune can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Click ...